Insights on SARS-CoV-2’s Mutations for Evading Human Antibodies: Sacrifice and Survival
Authors:
Preprint
Abstract
Recent mutations on the receptor binding domain (RBD) of the SARS-CoV-2’s spike protein have been manifested as the major cause of the wide and rapid spread of the virus. Especially, the variant B.1.351 in South Africa with the hallmark of triple mutations (N501Y, K417N and E484K) is worrisome. Quickly after the outbreak of this new variant, several studies showed that both N501Y and E484K can enhance the binding between RBD and the human ACE2 receptor. However, the mutation K417N seems to be unfavorable because it removes one interfacial salt-bridge. So far, it is still not well understood why the K417N mutation is selected in the viral evolution. Here, we show that despite the loss in the binding affinity (1.48 kcal/mol) between RBD and ACE2 the K417N mutation abolishes a buried interfacial salt-bridge between RBD and the neutralizing antibody CB6 and thus substantially reduces their binding energy by 9.59 kcal/mol, facilitating the variants to efficiently elude CB6 (as well as many other antibodies). Thus, when proliferating from person to person the virus might have adapted to the human immune system through evasive mutations. Taking into account limited and relevant experimental works in the field, we show that our theoretical predictions are consistent with existing experimental findings. By harnessing the revealed molecular mechanism for variants, it becomes feasible to redesign therapeutic antibodies accordingly to make them more efficacious.Keywords
All Related Versions
- Published version: Journal of Medicinal Chemistry, 65 (4), 2820.
This publication has 31 references indexed in Scilit:
- Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort studyThe Lancet Respiratory Medicine, 2021
- Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human serabioRxiv, 2021
- Could new COVID variants undermine vaccines? Labs scramble to find outNature, 2021
- Molecular Mechanism of the N501Y Mutation for Enhanced Binding between SARS-CoV-2’s Spike Protein and Human ACE2 ReceptorbioRxiv, 2021
- Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic datamedRxiv, 2021
- Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 BindingCell, 2020
- Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19Acta Pharmacologica Sinica, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2Science, 2020
- The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nature Microbiology, 2020